Max Healthcare stock jumps 6% as Citi backs FY30 growth

Stock leads Nifty 50 gainers on June 18

Max Healthcare Institute shares climbed 6% on June 18, emerging as the top gainer on the Nifty 50 during the session. The stock was trading at around ₹1,088 in afternoon deals, according to the figures provided. At that level, the hospital operator was valued at about ₹1.05 lakh crore. The move stood out against a relatively muted market, with the Nifty 50 up 0.17% at the same time. The broader backdrop, as cited, suggested positive market breadth with more than 2,000 stocks advancing on the NSE. Max Healthcare’s rally therefore came with both stock-specific catalysts and a supportive tape.

Citi reiterates buy, sets ₹1,240 target

Citi maintained a ‘buy’ rating on Max Healthcare and set a target price of ₹1,240 per share. The brokerage flagged a favourable risk-reward after the stock’s correction over the past year. As per Citi’s note in the provided text, Max Healthcare stock has declined around 18% over the past year, taking valuations back to historical averages. Citi said the valuation correction improves the stock’s attractiveness, while the company continues to offer a strong medium-term growth profile. The combination of a lower base valuation and ongoing capacity expansion was presented as the key supporting argument.

Growth outlook: 20% EBITDA CAGR projected for FY26-30

A central part of Citi’s thesis is the expectation of a 20% EBITDA compound annual growth rate (CAGR) between FY26 and FY30. The brokerage attributed this outlook to capacity additions and growth across Max Healthcare’s hospital network. Citi also expects revenue growth of around 15% in FY27. It further said growth could accelerate in FY28 as expansion initiatives begin contributing more meaningfully. The emphasis on expansion implies that execution and commissioning timelines will be closely tracked by investors.

Quarterly performance: profit up, expansion weighs on margins

The company reported a 3% year-on-year increase in net profit to ₹387 crore for Q4 FY26. Revenue rose 10% to ₹2,664 crore over the same period, based on the figures stated. The update also noted that margins were pressured by expansion, indicating that growth investments are affecting near-term profitability. This framing matters because hospital businesses often see a lag between capacity addition and steady utilisation. For investors, that makes operating leverage and ramp-up trajectories important markers.

Additional financial disclosures cited in the text

The provided material also includes a separate set of financial figures presented as “total income” and full-year changes. For Q4 FY26, total income was reported at ₹2,190.72 crore, up 3.68% quarter-on-quarter from ₹2,112.90 crore and up 11.96% year-on-year from ₹1,956.66 crore. For the full year FY26, total income stood at ₹8,536.07 crore, up 18.82% compared with ₹7,184.10 crore in FY25. Full-year profit for FY26 was reported at ₹1,442.41 crore, up 34.07% year-on-year from ₹1,075.88 crore in FY25. Separately, management commentary in the text described FY26 network gross revenue of ₹10,538 crore and operating EBITDA of ₹2,638 crore, with a 26.2% margin.

Broader market snapshot during the move

Alongside the stock-specific rally, the Sensex was up 152 points at 12:52 pm IST, as cited in the text. Market breadth was positive, with more than 2,000 stocks advancing on the NSE. Max Healthcare was described as the best-performing constituent on the Nifty 50 during the session. This context suggests the move played out in a constructive market environment, but still materially outperformed benchmark gains.

Stock price levels and return metrics referenced

The supplied content includes multiple price snapshots and return tables around the same period. One data point shows the stock trading at ₹1,026.15, up ₹2.05 (0.20%), with a previous close of ₹1,024.10 and open of ₹1,025.40. Intraday levels listed include a low of ₹1,017.20 and a high of ₹1,029.60, with a 52-week range of ₹903.00 to ₹1,314.30. A returns table in the text shows: 1 day 0.33%, 1 week 1.71%, 1 month -2.16%, 3 months 5.22%, 1 year -16.25%, 3 years 72.85%, and 5 years 312.36%. These figures underline that the one-year period has been weak even as longer-term returns remain strong.

Dividend update flagged by the company

The text notes that Max Healthcare announced the board recommended a final dividend of ₹2 per equity share (20%), subject to shareholder approval. The board meeting date cited for this recommendation is May 21, 2026. For income-focused investors, the timing and approval process will be a key procedural checkpoint. For other investors, dividend decisions can be viewed alongside capex needs tied to ongoing expansion.

Key numbers at a glance

Market impact: what investors are reacting to

The immediate market reaction combined price momentum with a supportive brokerage note. Citi’s emphasis on a “favourable risk-reward” after a sharp correction is a common trigger for re-rating discussions, particularly when coupled with a clear expansion roadmap. At the same time, the update that margins are being pressured by expansion is a reminder that near-term profitability can soften even when revenue grows. Investors typically balance these two threads: growth visibility from capacity additions versus the pace at which new beds and facilities reach steady utilisation. The session’s performance, where the stock led the Nifty 50 gainers, suggests that the brokerage call and growth narrative had more weight than near-term margin concerns on the day.

Analysis: why the Citi call matters for FY27-FY28 tracking

Citi’s stated revenue growth expectation of around 15% in FY27, with potential acceleration in FY28 as expansions contribute more, sets a timeline for how the market may evaluate execution. If commissioning is disciplined and ramp-ups are visible, the projected 20% EBITDA CAGR for FY26-30 becomes easier to underwrite. Conversely, if expansion keeps margins under pressure for longer, investors could focus more on return metrics and utilisation. The valuation angle is also central: Citi said the stock’s decline has brought valuations back to historical averages, which can change investor willingness to pay for forward growth. For a hospital operator, this becomes a debate about how quickly earnings power scales relative to the investment cycle.

Conclusion

Max Healthcare’s 6% jump on June 18 made it the top Nifty 50 gainer as investors weighed Citi’s buy call and ₹1,240 target against an expansion-led margin overhang. With Citi projecting a 20% EBITDA CAGR for FY26-30 and outlining a FY27-FY28 growth step-up, upcoming quarters will likely be assessed for execution progress and profitability trends. The company’s proposed final dividend of ₹2 per share, subject to shareholder approval, is another near-term milestone highlighted in the provided updates.